| Literature DB >> 35206040 |
Mariana Leitão1,2, Tatiana Ribeiro2, Pablo A García3, Luisa Barreiros4,5, Patrícia Correia2,4.
Abstract
Fermented foods have been used for several years all over the world, due to their unique nutritional characteristics and because fermentation promotes conservation and food security. Moreover, fermented foods and beverages have a strong impact on human gut microbiota. Papaya is the fruit of the Carica papaya plant, traditionally used as a medicinal fruit, but there are also references to the use of the fermented form of this fruit. The main purpose of this review is to provide an improved understanding of fermented papaya nutritional and health applications. A literature search was conducted in the PubMed and Google Scholar databases. Both in vitro and in vivo studies were included. According to the retrieved studies, fermented papaya has proven to be an excellent antioxidant and an excellent nutraceutical adjuvant in combined therapies against several diseases, such as Alzheimer's disease, allergic reactions, anticancer activity, and anemias. Therefore, it is concluded that fermented papaya has many benefits for human health and can be used as prevention or aid in the treatment of various diseases.Entities:
Keywords: fermented food; fermented papaya; health benefits; oxidative stress
Year: 2022 PMID: 35206040 PMCID: PMC8870802 DOI: 10.3390/foods11040563
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Immunomodulatory, antioxidant, and anticancer properties of fermented papaya.
| Preparation | Study Type | Dose | Model | Bioactive Effect | Reference |
|---|---|---|---|---|---|
| FPP® | In vitro study | 3 mg/mL | Murine monocyte/macrophage cell line RAW 264.7 treated with IFN-γ | FPP fractions in the presence | [ |
| FPP® | In vitro study | 1.2, 2.4, 4.8 mg/mL | AD cell model | Attenuated the | [ |
| FPP® | Randomized, Placebo-Controlled, | Group A: 9 g/day | 54 elderly patients randomly | FPP® supplemented group: | [ |
| FPP® | Pilot study | 6 g/day | 11 healthy nonsmoker patients | Plasma level | [ |
| FPP® | In vivo study | 6 mg/mouse/day | Specific pathogen-free male ICR mice with 8 weeks old | ↓ contact hypersensitivity | [ |
| FPEs | In vivo study | 5–30 mL FPEs/kg | 36 female mice divided into 6 groups | Protective effect of FPEs on mammary gland pathology | [ |
| FPEs | Clinical study | Group A: control group | 4 males and 8 females with cerebrovascular disease, 4 males and 3 females with neurodegenerative disease, and 1 male post-traumatic head injury divided into 3 groups | ↑ PBMC cytolytic activity | [ |
| FPP® | In vivo study | 50 mg/mouse/day | SHR | ↓ MC- PROXYL | [ |
| FPP® | In vivo study | 150, 300, or 450 mg/ | Mouse cancer model | Oral administration of FPP inhibited tumor growth | [ |
| In vitro study | 10 mg/mL | PBMC | ↑ IL-1β, TNFα and IFNγ | ||
| FPP® | In vivo study | 200, 400 mg/kg/day | 35 mice cancer models divided into 7 groups | ↓ tumor mass of about three to seven | [ |
| FPP® | In vivo study | 6 mg/mouse/day | 40 aging female mice model divided into 2 groups | ↑ telomerase activity | [ |
Aβ, substance β-amyloid; AD, Alzheimer’s disease; FPEs, fermented papaya extracts; GSH, free glutathione; GSH-Px, glutathione peroxidase; HMF, high molecular fraction (FPP®); IFN-γ, interferon- γ; IL-1β, interleukin-1β; iNOS, nitric oxide synthase; LMF, low molecular fraction (FPP®); MG, methylguanidine; NO, nitric oxide; PBMC, human peripheral blood mononuclear cells; ROS, reactive oxygen species; SHR, spontaneously hypertensive rats; SOD, superoxide dismutase; SOD-1, enzyme superoxide dismutase-1; TNF-α, tumor necrosis factor-α. ↑ increase, ↓ decrease.
Fermented papaya health benefits in congenital/acquired hemolytic anemias.
| Preparation | Study Type | Dose | Model | Bioactive Effect | Reference |
|---|---|---|---|---|---|
| FPP® | In vitro study | 10 mg/mL | Normal and thalassemic | ↑ glutathione content of RBC, platelets, and PMN leukocytes | [ |
| In vivo study | 50 mg/mouse/day | β-thalassemia mice models | |||
| Observational study | 3 g | 8 patients with β -thalassemia intermedia | |||
| FPP® | Observational study | 3 g 3 times/day | β- thalassemia group (8 patients with β-thal intermedia and 3 with β-thal major) | ↑ GSH | [ |
| 3 g 2 times/day | E-β- thalassemia group (7 patients) | ||||
| FPP® | Case report | 3 g 3 times/day | ↑ Hb level | [ | |
| FPP® | In vitro study | Incubation of HS-RBC for 2 h with 0.1 mg/mL | HS-RBC from 17 patients | ↑ Hb level | [ |
| In vivo study | 3 g 3 times/day | 10 (8 males and 2 females) HS patients |
FPPP®, fermented papaya preparation; GSH, reduced glutathione; Hb, free hemoglobin; HS, hereditary spherocytosis; LDH, lactate dehydrogenase; PMN, polymorphonuclear; RBC, red blood cells; ROS, reactive oxygen species. ↑ increase, ↓ decrease.
Fermented papaya skin benefits.
| Preparation | Study Type | Dose | Model | Bioactive Effect | Reference |
|---|---|---|---|---|---|
| BioRex® | In vitro study | 1–5 mg/mL | Peripheral blood neutrophils | Suppressed | [ |
| In vivo study | - | Thermal wound model in rats | ↓ wound area and bacterial burden; | ||
| FPP® | In vivo study | FPP group: 0.2 g/kg 5 days/week | Adult obese diabetic mice divided into 2 groups (FPP and placebo control) | ↑ NO and iNOS | [ |
| FPP® | Double-blind study | FPP group: 4.5 g 2 times/day | 60 healthy non-smoker males and females (40–65 years) divided into 2 groups | FPP supplementation: | [ |
FPP®, fermented papaya preparation; NO, nitric oxide; SOD, superoxide dismutase. ↑ increase, ↓ decrease.